Երկիր: Իռլանդիա
Լեզու: անգլերեն
Աղբյուրը: HPRA (Health Products Regulatory Authority)
BICALUTAMIDE
Hikma Farmaceutica (Portugal) SA
L02BB
BICALUTAMIDE
50 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
ANTI-ANDROGENS
Authorised
2010-02-12
PACKAGE LEAFLET: INFORMATION FOR THE USER BICALUTAMIDE HIKMA 50 MG FILM COATED TABLETS. Bicalutamide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Bicalutamide Hikma 50 mg is and what it is used for 2. Before you take Bicalutamide Hikma 50 mg 3. How to take Bicalutamide Hikma 50 mg 4. Possible side effects 5. How to store Bicalutamide Hikma 50 mg 6. Further information 1. WHAT BICALUTAMIDE HIKMA 50 MG IS AND WHAT IT IS USED FOR Bicalutamide Hikma 50 mg is used for the treatment of advanced prostate cancer. It is taken together with a drug known as an luteinising hormone-releasing hormone (LHRH) analogue which reduces the levels of androgens (male sex hormones) within the body, or with accompanying surgical removal of the testicles. The active ingredient of Bicalutamide Hikma 50 mg, bicalutamide, belongs to a group of medicines called non-steroidal anti-androgens. It blocks the undesired effect of the male sex hormones (androgens) and inhibits cell growth in the prostate in this way. 2. BEFORE YOU TAKE BICALUTAMIDE HIKMA 50 MG DO NOT TAKE BICALUTAMIDE HIKMA 50 MG - if you are allergic (hypersensitive) to bicalutamide or any of the other ingredients of Bicalutamide Hikma 50 mg - if you are already taking terfenadine or astemizole (for hay fever or allergy), or cisapride (for stomach disorders). Bi Կարդացեք ամբողջական փաստաթուղթը
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bicalutamide Hikma 50mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 50 mg bicalutamide. Excipient(s): Each tablet contains 62.7 mg of lactose monohydrate For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet White, round, biconvex film-coated tablets, with diameter of 6.5 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced prostate cancer in combination with Luteinizing hormone releasing hormone (LHRH) analogue therapy or surgical castration. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adult males including the elderly: one film coated tablet tablet (50mg) daily with or without food. Route: Oral The tablets should be swallowed whole with liquid. Treatment with bicalutamide should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration. Children and adolescents: Bicalutamide Hikma 50 mg is not-indicated in children and adolescents. Renal impairment: no dosage adjustment is necessary for patients with renal impairment. There is no experience with the use of bicalutamide in patients with severe renal impairment (creatinine clearance < 30 ml/mi.) Hepatic impairment: no dosage adjustment is necessary for patients with mild hepatic impairment. The medicinal product may accumulate in patients with moderate to severe hepatic impairment. (see Section 4.4). 4.3 CONTRAINDICATIONS Bicalutamide Hikma 50 mg is contra-indicated in women, children and adolescents (see Section 4.6). Bicalutamide Hikma 50 mg is contraindicated in patients hypersensitivity to the active substance or any of the excipients of this product. Co-administration of terfenadine, astemizole or Կարդացեք ամբողջական փաստաթուղթը